Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ... Helsinn Healthcare S.A.January 12, 2021 GMT Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS095...